Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Research indicates that DSIP has a stress protective effect by modulating the activity of GABA in the brain
Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness
Zhang XW, Li X, Yin Y, Wang M, Wang YF, Chen JY, et al
Furthermore, studies have shown GLP-1RAs are associated with a modest decrease in intraocular pressure, particularly in individuals with elevated baseline intraocular pressure (IOP) [103], and a reduced risk of developing glaucoma in patients with T2DM [104]
US$ 21.00
US$ 27.84
US$ 25.68
US$ 29.00
US$ 25.45
US$ 29.09
US$ 28.07
US$ 23.42
US$ 29.29
US$ 26.61
